Dean Macfarland Net Worth

What's Dean Macfarland's mailing address?

Dean's mailing address filed with the SEC is C/O CUTERA, INC., 3240 BAYSHORE BLVD., BRISBANE, CA, 94005.

Insiders trading at Cutera Inc

Over the last 21 years, insiders at Cutera Inc have traded over $58,122,420 worth of Cutera Inc stock and bought 1,064,292 units worth $26,108,997 . The most active insiders traders include Kevin P Connors, J Daniel Plants, and David A Gollnick. On average, Cutera Inc executives and independent directors trade stock every 22 days with the average trade being worth of $13,243. The most recent stock trade was executed by Michael Karavitis on 14 May 2024, trading 63,603 units of CUTR stock currently worth $165,368.

What does Cutera Inc do?

cutera was established in the san francisco bay area (brisbane) in 1998 by veteran laser and optical engineers. as the pioneer of nd:yag technology, cutera® is the trusted authority in face + body energy-based medical aesthetic technologies that practitioners around-the-world turn to for innovation, sophistication and performance. at cutera, we’re always looking forward; developing new solutions, products and industry-leading services designed around the needs of medical aesthetic community—delivering better results, faster and safer than ever before. cutera’s premium portfolio of products include: xeo®, trusculpt® and excel v™. in 2014, cutera introduced two new exciting additions to their family of premium products: excel hr™ for high-speed, comfortable, hair removal and enlighten™, the industry’s first picosecond + nanosecond + 2 wavelength high-powered laser system. today, our worldwide presence is represented in 40 countries, with direct operations in north america, france, austra

Cutera Inc executives and stock owners

Cutera Inc executives and other stock owners filed with the SEC include:

• David Mowry,
  Chief Executive Officer, Director
• R. Jason Richey,
  President
• David H. Mowry,
  CEO & Director
• Rohan Seth,
  Chief Financial Officer
• Gregory Barrett,
  Independent Director
• J. Daniel Plants,
  Independent Chairman of the Board
• Timothy O'Shea,
  Independent Director
• Joseph Whitters,
  Independent Director
• Katherine Zanotti,
  Independent Director
• J. Daniel Plants,
  Exec. Chairman
• Anne Werdan,
  Director - Investor Relations
• Darren Alch,
  Vice President, General Counsel, Secretary
• Rohan Seth,
  Chief Financial Officer
• Dr. Michael Karavitis,
  Exec. VP & Chief Technology Officer
• Jerry P Widman,
  Director
• Miguel Pardos,
  EVP, International Sales
• James A. Reinstein,
  President and CEO
• Clinton Severson,
  Director
• David B Apfelberg,
  Director
• Larry Laber,
  EVP, North America Sales
• Kevin P Connors,
  President and CEO
• David A Gollnick,
  VP of Research and Development
• Thomas John Liolios,
  VP of International
• Keith J Sullivan,
  Director
• Nicholas Sheridan Lewin,
  Director
• Sandra A. Gardiner,
  EVP & Chief Financial Officer
• Elisha W Finney,
  Director
• Guy P Nohra,
  Director
• Michael J Levernier,
  VP of Clinical Development
• Associates Iii Lp Medventure,
  10% owner
• Guy Palta California Partne...,
  
• Kathleen A Maynor,
  VP of Regulary Affairs & QA
• Associates Management Iii C...,
  10% owner
• Guy Palta Partnersalta Cali...,
  
• Dean Macfarland,
  
• Michael W Sasnett,
  
• W Mark Lortz,
  Director
• Leonard C De Benedictis,
  Chief Technology Officer
• White Annette Campbell,
  Director
• Robert John Jr Shine,
  VP of International
• Ronald J Santilli,
  CFO & VP of Finance and Admin.
• John Connors,
  VP of North American Sales
• Jeryl L Hilleman,
  Director
• Michael Karavitis,
  EVP, Chief Technology Officer
• Sheila Hopkins,
  Director
• Juliane Park,
  Director
• Janet D. Widmann,
  Director
• Kevin J Cameron,
  Director
• Stuart Drummond,
  Interim CFO
• Taylor C. Harris,
  Chief Executive Officer
• Jeffrey S Jones,
  Chief Operating Officer
• Stephana Eilene Patton,
  Chief Legal Officer